clinical trial · NCT07722728
A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
Bostal Drug Delivery Co., Ltd·phase3·not yet recruiting·n = 84
Schizophrenia30 mg B222770 mg B2227150 mg B2227Vraylar® 1.5 mgVraylar® 3.0 mgVraylar® 4.5 mgVraylar® 6.0 mg
brief summary
The study is to evaluate the pharmacokinetic profile of B2227 Extended-Release Injectable Suspension against Vraylar® Cariprazine capsules of AbbVie Inc. in participants with schizophrenia.
started
Aug 1, 2026
primary completion
Aug 1, 2027
completion
Dec 1, 2027
last updated
Jul 23, 2026
official title
An Open-label, Randomized, Single-dose (Long-acting Injectable) or Multiple-dose (Oral) Clinical Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol